

Official Journal of the European Union

C 215



English edition

Information and Notices

Volume 60

5 July 2017

Contents

II *Information*

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2017/C 215/01	Communication from the Commission — Guidelines on non-financial reporting (methodology for reporting non-financial information)	1
---------------	---	---

IV *Notices*

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

2017/C 215/02	EU Action Plan on Drugs 2017-2020	21
---------------	---	----

European Commission

2017/C 215/03	Euro exchange rates	59
---------------	---------------------------	----

EN

Objective	Action	Timetable	Responsible party	Indicator(s)	Data collection/assessment mechanisms
	<p>8. a. Scale up where applicable, availability, coverage and access to risk and harm reduction services e.g. needle and syringe exchange programmes, opioid substitution treatment, opioid overdose management programmes, to lessen the negative consequences of drug use and to prevent and to substantially reduce the number of direct and indirect drug-related deaths and infectious blood-borne diseases associated with drug use but not limited to HIV and viral hepatitis, as well as sexually transmittable diseases and tuberculosis in accordance with the WHO recommendation on the comprehensive package of health services for people who inject drugs</p> <p>b. Better prevent drug related deaths according to national circumstances as for example in the case of opiates, by providing access to authorised pharmaceutical dosage forms of medicinal products containing naloxone specifically certified to treat opioid overdose symptoms by trained laypersons in the absence of medical professionals</p>	Ongoing	MS EMCDDA COM	<ul style="list-style-type: none"> — Over-arching indicators 2, 3, 4, 11 — Extent of increased availability of and access to evidence-based risk and harm reduction measures in MS where applicable — Overview of exchanges of best practices on risk and harm reduction measures — Number of MS reaching the WHO recommendation on the comprehensive package of health services for people who inject drugs: <ul style="list-style-type: none"> — Needle/Syringe programmes — Opioid substitution treatment — HIV testing and counselling — HIV treatment and care — Condom programmes — Behavioural interventions — Prevention and management of hepatitis, tuberculosis and mental health — Sexual reproductive health interventions — Naloxone training for laypersons as an irreplaceable prerequisite for safe take-home programmes 	<p>EMCDDA Reporting/ Reitox network national reporting package</p> <p>MS Reporting</p> <p>Civil Society Forum on Drugs</p> <p>Civil Society Forum on HIV/AIDS, Viral Hepatitis and Tuberculosis</p>